|
- Drugs (psychoactive) - World Health Organization (WHO)
The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important
- WHO Drug Information
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers
- Alcohol, Drugs and Addictive Behaviours
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours
- WHO launches new framework to tackle drug resistance to HIV, hepatitis . . .
WHO has released the Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030, a landmark roadmap to address the growing threat of drug resistance and safeguard progress toward ending AIDS and the epidemics of hepatitis B, hepatitis C and sexually transmitted infections (STIs) as public health concerns
- 1. 3 Drug-resistant TB - World Health Organization (WHO)
Other patterns of drug resistance There were an estimated 1 5 million incident cases (95% UI: 0 59–2 4 million) of isoniazid-resistant TB in 2024, including people with both rifampicin-susceptible and rifampicin-resistant TB
- WHO announces landmark changes in treatment of drug-resistant tuberculosis
The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR RR-TB)
- WHO issues global guideline on the use of GLP-1 medicines in treating . . .
To address the growing global health challenge of obesity, which affects more than 1 billion people, WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease
- WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Module 4: treatment and care encompass all current recommendations for managing drug-susceptible and drug-resistant TB, alongside patient care and support strategies Developed according to WHO’s rigorous standards, the guidelines rely on the latest evidence reviews and the GRADE methodology to evaluate evidence quality and determine the strength of each recommendation Primarily aimed at
|
|
|